Literature DB >> 3028192

Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups.

J S Reif, P A Webb, T P Monath, J K Emerson, J D Poland, G E Kemp, G Cholas.   

Abstract

In 1982-1983, an epizootic of vesicular stomatitis occurred in the western United States. Veterinarians, research workers, and regulatory personnel who were exposed to vesicular stomatitis virus were examined for patterns of human infection and prevalence of vesicular stomatitis New Jersey serotype neutralizing antibody. Insight into the mechanism of transmission was sought by comparing activities of antibody-positive and antibody-negative persons. A statistically significant risk factor was a history of infected animals sneezing in the face of serosurvey participants. Elevated odds ratios were also calculated for those who usually examined the oral cavity of affected animals, had open wounds on hands or arms, and had exposure to saliva through the eye or skin. Relatively intimate direct contact was required; a higher risk was associated with examining horses than cattle. Neutralizing antibody prevalence was significantly higher among exposed persons with illness (23%) than in exposed persons without a history of clinical illness (7%). Overall, however, infectivity of VSNJ for humans during the epizootic was low.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028192     DOI: 10.4269/ajtmh.1987.36.177

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

1.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Authors:  Selidji T Agnandji; Angela Huttner; Madeleine E Zinser; Patricia Njuguna; Christine Dahlke; José F Fernandes; Sabine Yerly; Julie-Anne Dayer; Verena Kraehling; Rahel Kasonta; Akim A Adegnika; Marcus Altfeld; Floriane Auderset; Emmanuel B Bache; Nadine Biedenkopf; Saskia Borregaard; Jessica S Brosnahan; Rebekah Burrow; Christophe Combescure; Jules Desmeules; Markus Eickmann; Sarah K Fehling; Axel Finckh; Ana Rita Goncalves; Martin P Grobusch; Jay Hooper; Alen Jambrecina; Anita L Kabwende; Gürkan Kaya; Domtila Kimani; Bertrand Lell; Barbara Lemaître; Ansgar W Lohse; Marguerite Massinga-Loembe; Alain Matthey; Benjamin Mordmüller; Anne Nolting; Caroline Ogwang; Michael Ramharter; Jonas Schmidt-Chanasit; Stefan Schmiedel; Peter Silvera; Felix R Stahl; Henry M Staines; Thomas Strecker; Hans C Stubbe; Benjamin Tsofa; Sherif Zaki; Patricia Fast; Vasee Moorthy; Laurent Kaiser; Sanjeev Krishna; Stephan Becker; Marie-Paule Kieny; Philip Bejon; Peter G Kremsner; Marylyn M Addo; Claire-Anne Siegrist
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

Review 2.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

3.  Attenuated vesicular stomatitis viruses as vaccine vectors.

Authors:  A Roberts; L Buonocore; R Price; J Forman; J K Rose
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 4.  Understanding and altering cell tropism of vesicular stomatitis virus.

Authors:  Eric Hastie; Marcela Cataldi; Ian Marriott; Valery Z Grdzelishvili
Journal:  Virus Res       Date:  2013-06-22       Impact factor: 3.303

Review 5.  Prospects for immunisation against Marburg and Ebola viruses.

Authors:  Thomas W Geisbert; Daniel G Bausch; Heinz Feldmann
Journal:  Rev Med Virol       Date:  2010-11       Impact factor: 6.989

6.  Trajectory analysis of winds and vesicular stomatitis in North America, 1982-5.

Authors:  R F Sellers; A R Maarouf
Journal:  Epidemiol Infect       Date:  1990-04       Impact factor: 2.451

7.  Phylodynamics of Alagoas vesiculovirus in Brazil.

Authors:  Antônio Augusto Fonseca Júnior; Mateus Laguardia-Nascimento; Aline Aparecida Silva Barbosa; Valdenia Lopes da Silva Gonçalves; Anapolino Macedo de Oliveira; Anselmo Vasconcelos Rivetti Júnior; Marcelo Fernandes Camargos
Journal:  Braz J Microbiol       Date:  2022-05-13       Impact factor: 2.214

8.  In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation.

Authors:  J Erik Johnson; John W Coleman; Narender K Kalyan; Priscilla Calderon; Kevin J Wright; Jennifer Obregon; Eleanor Ogin-Wilson; Robert J Natuk; David K Clarke; Stephen A Udem; David Cooper; R Michael Hendry
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

9.  Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.

Authors:  David K Clarke; Farooq Nasar; Siew Chong; J Erik Johnson; John W Coleman; Margaret Lee; Susan E Witko; Cheryl S Kotash; Rashed Abdullah; Shakuntala Megati; Amara Luckay; Becky Nowak; Andrew Lackner; Roger E Price; Peter Little; Narender Kalyan; Valerie Randolf; Ali Javadian; Timothy J Zamb; Christopher L Parks; Michael A Egan; John Eldridge; Michael Hendry; Stephen A Udem
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

10.  Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates.

Authors:  J Erik Johnson; Farooq Nasar; John W Coleman; Roger E Price; Ali Javadian; Kenneth Draper; Margaret Lee; Patricia A Reilly; David K Clarke; R Michael Hendry; Stephen A Udem
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.